All News

RheumNow Podcast square

Don’t Buy Guitars (12.6.2024)

Jack Cush, MD

This year at ACR24, the RheumNow faculty and reporters were prolific, generating >800 Tweets, 56 written articles, 117 Videos and 28 podcasts – all in 4 days! You can best review and learn ACR24 by A) Rheumatology Roundup; b) Topic Panel videos; and c) Topic podcasts.

Read Article
pregnant, pregnancy, mother, fertility

Infertility linked to post-childbrith onset of systemic autoimmune disease

EurekAlert!

Women who experience infertility but do not use fertility treatments have a higher risk of developing a group of conditions called systemic autoimmune rheumatic diseases (SARD) in the nine years after a naturally conceived birth compared to women without fertility problems.

Read Article
IgG4.criteria.jpg

Inebilizumab for Treatment of IgG4-Related Disease

Jack Cush, MD

Inebilizumab is an monoclonal antibody that targets and depletes CD19+ B cells and has been studied in adults with IgG4-related disease.

Read Article
eyes

Phase 2b Study of Ianalumab in Sjögren's

Jack Cush, MD

A 52-week has demonstrated the safety and efficacy of ianalumab, a dual B cell depleter) in patients with active Sjögren's disease (SjD).

Read Article
Roundup cover

ACR24: Rheumatology Roundup

Jack Cush, MD

Join Drs. Jack Cush and Artie Kavanaugh as they review 15+ presentations and abstracts from the 2024 ACR Convergence meeting in Washington, DC.

Read Article
Full Read Review of the Pulmonary Manifestations in Antisynthetase Syndrome (good reference!) https://t.co/gBLYRmHKE4 https://t.co/pUWmQCHk0N

Links:

Dr. John Cush RheumNow ( View Tweet)
Novel TYK2 inhibitor Zasocitinib Interest in tyrosine kinase 2 (TYK2), a member of the JAK family, is growing following the success of JAK inhibitors in treating rheumatic diseases. TYK2 is crucial for immune activation but has minimal involvement in metabolic and hematopoietic… https://t.co/eDcx4AAnAs https://t.co/Y8Rso7h5t2
Dr. John Cush RheumNow ( View Tweet)
Autoantibodies, found in over half of adult and paediatric patients with idiopathic inflammatory myopathies (IIMs), these correlate with clinical phenotypes, aiding in classification and prognosis. https://t.co/ZRXqtEec6s https://t.co/jkUe9bRlmU

Links:

Dr. John Cush RheumNow ( View Tweet)
ANA+ and no Autoimmune Disease? Check the liver Dr. Janet Pope discusses abstract 0627, presented at #ACR24. https://t.co/4HV2kqjibL https://t.co/kmVcvUZtRQ

Links:

Dr. John Cush RheumNow ( View Tweet)
💊Litifilimab- another new molecule for SLE Anti BDCA2 🎯 In cutaneous lupus👉 👉Decrease CLASI score 👉Decrease IFN induced MxA expression #ACR2024 #ACRAmbassador https://t.co/AeJOGhVXIR

Links:

Ritasman Baisya RitasmanB ( View Tweet)
#ACR24: What Exactly do JAKs and TYKs Do? Let me start by confessing something embarrassing: the immune system is just too complex for me to understand. I suspect the onslaught of new drugs with new mechanisms at ACR 2024 may have left many of you feeling similarly.… https://t.co/HkhZJBxDdO https://t.co/xYeSpHS2dD
Dr. John Cush RheumNow ( View Tweet)
COVID Associated Immune Disease Dr. Len Calabrese reports on a session he participated in discussing if Covid-19 is associated or causal for autoimmune disease. Reporting from #ACR24 https://t.co/vFdlf9XVzf https://t.co/JhpglNVIt7

Links:

Dr. John Cush RheumNow ( View Tweet)
Hypoxia seems to exacerbate neutrophil activation by ANCA - enhanced F-Actin polymerization - enhanced NET formation Could hypoxia predilection in certain tissues (kidney, lung) lead to the AAV phenotypic disease patterns? @RheumNow #ACR24 https://t.co/KxaeMvkd2t

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Prior studies have shown that IFN is increased in non-lesional skin of SLE pts. In this study, they found a ⬆️ expression of IFN stimulated genes (ISGs) in pts w/ a history of CLE. No correlation w/ CLASI act & IFN scores but only few pts. @RheumNow #ACR24 abs2678 https://t.co/cPT6yPkoCb

Links:

sheila RHEUMarampa ( View Tweet)
Late breaking abstract L17 CAR-NK Therapy for Refractory SLE. In a trial of 20 severe SLE patients: - 75% achieved LLDAS, 50% achieved DORIS remission at 6 months - B cell reconstitution: 2–3 months post-treatment - Safety: 2 mild cytokine release syndrome with fever; no severe… https://t.co/MS8cutm48o

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Mitochondria: the powerhouse of the cell—but the fuel behind gout flares? #ACR24 @RheumNow https://t.co/lV4dovLV18

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)

In prelim analysis of this controlled clinical trial, SLE pts w/ active dse who weres given addtl NAC for 3 mos had significantly reduced dse activity. Mechanism? NAC reduces rapamycin (mTOR) activation. Common AEs: nausea, vomiting @RheumNow #ACR24 abs2677 https://t.co/E4w2Qd7RwP

Links:

sheila RHEUMarampa ( View Tweet)
#Positive #RCT of #Nipocalimab a FcRn receptor inhibitor in #Sjogrens #Disease 👏Phase 2 +RCT ESSSDAI and ESPRI both improved 🤷‍♀️what it means to lower #antibodoes #Ro #La Excited for Phase 3 results #ACRBest #ACR24 @RheumNow @ACRheum abst#2527 https://t.co/NeeYT7VR16

Links:

Janet Pope Janetbirdope ( View Tweet)
Autoantibody tests are everywhere, but how do we make sense of them? With the proper algorithms, can we go beyond interpretation to predicting autoimmunity before it develops? Check out my article: Taking the AI out of AutoImmunity https://t.co/d3ZNYWQaaQ @RheumNow #ACR24

Links:

Akhil Sood MD AkhilSoodMD ( View Tweet)

Paraoxonase-1: Possible Biomarker for Progression to RA Dr. Jonathan Kay discusses abstract 0464, Increases in Paraoxonase-1 Activity over Time Associates with Reduced Risk of Incident Inflammatory Arthritis in an Anti-Citrullinated Protein Antibody-Positive Population,… https://t.co/yhcCrrvjxH https://t.co/caf5dUvrOQ
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×